Invesco Dynamic Biotechnology & Genome ETF
Invesco Dynamic Biotechnology & Genome ETF (PBE) Stock Overview
Explore Invesco Dynamic Biotechnology & Genome ETF’s financial performance, market position, analyst ratings, and future outlook.
PBE Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Invesco Dynamic Biotechnology & Genome ETF (PBE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $76.41.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of N/A and a market capitalization of 291.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Wheaton, MA
2005